首页> 外文期刊>International Journal of Pharmaceutics >Evaluating the inter and intra batch variability of protein aggregation behaviour using Taylor dispersion analysis and dynamic light scattering
【24h】

Evaluating the inter and intra batch variability of protein aggregation behaviour using Taylor dispersion analysis and dynamic light scattering

机译:使用泰勒色散分析和动态光散射评估蛋白质聚集行为的批间和批内变异性

获取原文
获取原文并翻译 | 示例
           

摘要

Biosimilar pharmaceuticals are complex biological molecules that have similar physicochemical properties to the originator therapeutic protein. They are produced by complex multi-stage processes and are not truly equivalent. Therefore, for a biosimilar to be approved for market it is important to demonstrate that the biological product is highly similar to a reference product. This includes its primary and higher order structures and its aggregation behaviour. Representative lots of both the proposed biosimilar and the reference product are analysed to understand the lot-to-lot variability of both drug substances in the manufacturing processes. Whilst it is not easy to characterise every variation of a protein structure at present additional analytical technologies need to be utilised to ensure the safety and efficacy of any potential biosimilar product. We have explored the use of Taylor dispersion analysis (TDA) to analyse such batch to batch variations in the model protein, bovine serum albumin (BSA) and compared the results to that obtained by conventional dynamic light scattering analysis (DLS). Inter and intra batch differences were evident in all grades of BSA analysed. However, the reproducibility of the TDA measurements, enabled the stability and reversibility of BSA aggregates to be more readily monitored. This demonstrates that Taylor dispersion analysis is a very sensitive technique to study higher order protein states and aggregation. The results, here, also indicate a correlation between protein purity and the physical behaviour of the samples after heat shocking. Here, the protein with the highest quoted purity resulted in a reduced increase in the measured hydrodynamic radius after heat stressing, indicating that less unfolding/aggregation had occurred. Whilst DLS was also able to observe the presence of aggregates, its bias towards larger aggregates indicated a much larger increase in hydrodynamic radii and is less sensitive to small changes in hydrodynamic radii. TDA was also able to identify low levels of larger aggregates that were not observed by DLS. Therefore, given the potential for immunogenicity effects that may result from such aggregates it is suggested that TDA may be suitable in the evaluating detailed batch to batch variability and process induced physical changes of biopharmaceuticals and biosimilars.
机译:生物仿制药是具有与起始治疗蛋白相似的理化特性的复杂生物分子。它们是通过复杂的多阶段过程生产的,并非真正等效。因此,对于要批准上市的生物仿制药,重要的是证明该生物制品与参考产品高度相似。这包括其主要和较高阶的结构及其聚集行为。分析拟议的生物仿制药和参考产品的代表性批次,以了解两种原料药在生产过程中的批次间差异。虽然目前很难表征蛋白质结构的每个变异,但仍需要使用其他分析技术来确保任何潜在生物仿制药的安全性和有效性。我们已经探索了使用泰勒分散分析(TDA)来分析模型蛋白,牛血清白蛋白(BSA)中此类批次之间的差异,并将结果与​​通过常规动态光散射分析(DLS)获得的结果进行比较。在所分析的所有等级的BSA中,批次间和批次内差异都是明显的。但是,TDA测量值的可重复性使BSA聚集体的稳定性和可逆性更易于监控。这表明泰勒分散分析是研究高阶蛋白质状态和聚集的非常灵敏的技术。在此,结果还表明热冲击后蛋白质纯度与样品的物理行为之间的相关性。在此,具有最高引用纯度的蛋白质在热应激后导致测得的流体动力学半径的增加减少,表明发生的解折叠/聚集较少。尽管DLS还能够观察到聚集体的存在,但它偏向较大的聚集体表明流体动力半径的增加幅度更大,并且对流体动力半径的微小变化不那么敏感。 TDA还能够识别出DLS所未观察到的低水平的较大聚集体。因此,鉴于这种聚集体可能产生的免疫原性效应,建议TDA可能适用于评估详细的批次间差异和过程诱导的生物制药和生物类似物的物理变化。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号